1. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico

    The Breast (2014)

    Introduction Evidence regarding the outcomes of Hispanic women with breast cancer is lacking. We analyzed women with HER2+ disease treated with trastuzumab-based neoadjuvant chemotherapy in Mexico.
  2. Challenges to effective cancer control in China, India, and Russia.

    The Lancet Oncology 15(5):489 (2014) PMID 24731404

    Cancer is one of the major non-communicable diseases posing a threat to world health. Unfortunately, improvements in socioeconomic conditions are usually associated with increased cancer incidence. In this Commission, we focus on China, India, and Russia, which share rapidly rising cancer incide...
  3. Access to care issues adversely affect breast cancer patients in Mexico: oncologists' perspective.

    BMC Cancer 14:658 (2014) PMID 25199766 PMCID PMC4165903

    Despite recently implemented access to care programs, Mexican breast cancer (BC) mortality rates remain substantially above those in the US. We conducted a survey among Mexican Oncologists to determine whether practice patterns may be responsible for these differences. A web-based survey was sen...
  4. Outcomes of breast cancer in Brazil related to health care coverage: a retrospective cohort study.

    Cancer Epidemiology Biomarkers & Prevention 23(1):126 (2014) PMID 24165578

    Breast cancer is the most common malignancy in women in Brazil. Differences between patients with public versus private healthcare coverage about general characteristics, disease presentation, treatment of primary tumors, and clinical outcomes have not been fully investigated. A national, retros...
  5. Cancer control in Chile - Authors' reply.

    The Lancet Oncology 14(9):e338 (2013) PMID 23896269

  6. Cancer control in Chile – Authors' reply

    The Lancet Oncology 14(9):e338 (2013)

  7. Planning cancer control in Latin America and the Caribbean

    The Lancet Oncology 14(5):391 (2013)

    Non-communicable diseases, including cancer, are overtaking infectious disease as the leading health-care threat in middle-income and low-income countries. Latin American and Caribbean countries are struggling to respond to increasing morbidity and death from advanced disease. Health m...
  8. Planning cancer control in Latin America and the Caribbean.

    The Lancet Oncology 14(5):391 (2013) PMID 23628188

    Non-communicable diseases, including cancer, are overtaking infectious disease as the leading health-care threat in middle-income and low-income countries. Latin American and Caribbean countries are struggling to respond to increasing morbidity and death from advanced disease. Health ministries ...
  9. Breast cancer in young women in Latin America: an unmet, growing burden.

    Oncologist 18(12):1298 (2013) PMID 24277771 PMCID PMC3868424

    Breast cancer (BC) is the leading cause of malignancy-related deaths among women aged ≤45 years. There are unexplored and uncertain issues for BC in this particular group in Latin America. The aim of this study is to evaluate BC incidence and mortality among young women and related clinicopathol...
  10. Breast cancer in young women in Latin America: an unmet, growing burden.

    Oncologist 18(12):1298 (2013) PMID 24277771 PMCID PMC3868424

    Breast cancer (BC) is the leading cause of malignancy-related deaths among women aged ≤45 years. There are unexplored and uncertain issues for BC in this particular group in Latin America. The aim of this study is to evaluate BC incidence and mortality among young women and related clinicopathol...
  11. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial

    The Lancet Oncology 14(1):88 (2013)

    Background Worldwide, many patients with HER2-positive early stage breast cancer do not receive trastuzumab—the standard adjuvant treatment. We investigated the efficacy and safety of adjuvant lapatinib for patients with trastuzumab-naive HER2-positive early-stage breast canc...
  12. Adjuvant lapatinib for women with early-stage HER2-positive breast cancer: a randomised, controlled, phase 3 trial.

    The Lancet Oncology 14(1):88 (2013) PMID 23234763

    Worldwide, many patients with HER2-positive early stage breast cancer do not receive trastuzumab-the standard adjuvant treatment. We investigated the efficacy and safety of adjuvant lapatinib for patients with trastuzumab-naive HER2-positive early-stage breast cancer, started at any time after d...
  13. Breast cancer in young women in Latin America: an unmet, growing burden.

    Oncologist 18 Suppl:26 (2013) PMID 24334479

    Breast cancer (BC) is the leading cause of malignancy-related deaths among women aged ≤ 45 years. There are unexplored and uncertain issues for BC in this particular group in Latin America. The aim of this study is to evaluate BC incidence and mortality among young women and related clinicopatho...
  14. Breast cancer in Mexico: a growing challenge to health and the health system

    The Lancet Oncology 13(8):e335 (2012)

    Breast cancer is a major public health issue in low-income and middle-income countries. In Mexico, incidence and mortality of breast cancer have risen in the past few decades. Changes in health-care policies in Mexico have incorporated programmes for access to early diagnosis and treat...
  15. Breast cancer in Mexico: a growing challenge to health and the health system.

    The Lancet Oncology 13(8):e335 (2012) PMID 22846838

    Breast cancer is a major public health issue in low-income and middle-income countries. In Mexico, incidence and mortality of breast cancer have risen in the past few decades. Changes in health-care policies in Mexico have incorporated programmes for access to early diagnosis and treatment of th...
  16. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico

    The Breast (2012)

    Introduction Evidence regarding the outcomes of Hispanic women with breast cancer is lacking. We analyzed women with HER2+ disease treated with trastuzumab-based neoadjuvant chemotherapy in Mexico.
  17. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico

    The Breast (2012)

    Introduction Evidence regarding the outcomes of Hispanic women with breast cancer is lacking. We analyzed women with HER2+ disease treated with trastuzumab-based neoadjuvant chemotherapy in Mexico.
  18. Outcomes of Hispanic women with lymph-node positive, HER2 positive breast cancer treated with neoadjuvant chemotherapy and trastuzumab in Mexico

    The Breast (2012)

    Introduction Evidence regarding the outcomes of Hispanic women with breast cancer is lacking. We analyzed women with HER2+ disease treated with trastuzumab-based neoadjuvant chemotherapy in Mexico.
  19. E-cadherin expression in sporadic gastric cancer from Mexico: exon 8 and 9 deletions are infrequent events associated with poor survival.

    Human Pathology 36(1):29 (2005) PMID 15712179

    Aberrant expression and mutation of E-cadherin is frequent in gastric carcinoma (GC) especially of the diffuse type. The frequency of CDH1 (gene encoding E-cadherin) mutation in populations with high incidence of diffuse GC and its prognostic significance is unknown. One hundred seventy-seven ga...
  20. E-Cadherin expression in Sporadic Gastric cancer from Mexico: Exon 8 and 9 deletions are infrequent events associated with poor survival

    Human Pathology 36(1):29 (2005)

    Aberrant expression and mutation of E-cadherin is frequent in gastric carcinoma (GC) especially of the diffuse type. The frequency of CDH1 (gene encoding E-cadherin) mutation in populations with high incidence of diffuse GC and its prognostic significance is unknown. One hundred seve...